Lilly is considering expanding the availability of lower-priced vials of its blockbuster obesity drug Zepbound ...

The government is expected to pay lower prices for Ozempic and Wegovy starting in 2027. The Trump administration will decide ...

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

The Biden administration said Medicare will negotiate discounts with drug companies on 15 drugs prescribed to treat cancer, ...

In a live taping of "The Readout LOUD" at #JPM25, Eli Lilly CEO Dave Ricks talks Trump, Medicare's drug price negotiation, ...

Just how much Medicare price negotiations will negatively impact Novo Nordisk, though, depends on what the final negotiated ...

Ozempic was one of the 15 drugs selected for the 2027 Medicare drug price negotiation program three days before ...

Eli Lilly's diverse portfolio shows broad growth, with significant contributions from oncology and other therapeutic areas.

Neither Medicare nor Medicaid covers weight loss medications like Zepbound. While Eli Lilly doesn’t offer specific pricing information for Zepbound, it has a savings program. With eligible ...

Eli Lilly's stock tumbled 8% on Tuesday after it forecast fourth-quarter sales of weight-loss drug Zepbound below Wall Street ...

Unfortunately for the company, however, the early glimpse at its fourth-quarter performance doesn’t seem to be going over ...

The updated guidance, which was largely driven by lower-than-anticipated sales of GLP-1 blockbusters Mounjaro and Zepbound, ...